SFT2D2 and prostate cancer: This research provides comprehensive evidence that chimeric SFT2D2‐TBX19 promotes prostate cancer progression by encoding the TBX19‐202 protein and stabilizing mitochondrial ATP synthase via ATP5F1A phosphorylation.